Sami Diab, MD, highlights the use of the BCI for guiding adjuvant hormonal therapy decision-making in patients with early-stage, HR-positive breast cancer.

Sami Diab, MD, discusses the value of the Breast Cancer Index for identifying disease recurrence risk in breast cancer after adjuvant endocrine therapy.

Sami Diab, MD, discusses facets of individualized risk assessment for premenopausal patients with early-stage HR-positive, node-negative breast cancer.

Sami Diab, MD, discusses the use of genomic assays for determining whether extended adjuvant therapy is needed for patients with breast cancer.